Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Teriparatide Clear all
Completed Phase 4 Interventional Results available

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

NCT00557310
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Tucson, Arizona • Lakewood, Colorado • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

NCT00131469
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Teriparatide (FORTEO), Placebos
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

NCT00035256
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide, raloxifene HCl, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Maywood, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 14, 2007 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

NCT01250145
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
LY333334, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

NCT01309399
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, placebo
Drug · Other
Lead sponsor
Health Research, Inc.
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

NCT00887354
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Risedronate, Placebo, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury

NCT01225055
View directory record Official record
Conditions
Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions
Teriparatide, vibration
Drug · Device
Lead sponsor
Thomas J. Schnitzer
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion

NCT01292252
View directory record Official record
Conditions
Lumbar Spondylosis, Lumbar Spondylolisthesis, Adult Degenerative Lumbar Scoliosis
Interventions
teriparatide, Placebo
Biological
Lead sponsor
Shane Burch
Other
Eligibility
60 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 3, 2026, 6:54 PM EDT
Not listed No phase listed Observational

Medication-related Osteonecrosis of the Jaw (MRONJ) Registry

NCT02932501
View directory record Official record
Conditions
Medication-related Osteonecrosis of the Jaw, Bisphosphonate-Associated Osteonecrosis of the Jaw
Interventions
Conservative treatment, Surgical treatment, Adjuvant non-surgical treatment
Procedure
Lead sponsor
AO Clinical Investigation and Publishing Documentation
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 3, 2026, 6:54 PM EDT
Not listed Phase 4 Interventional

The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

NCT01173081
View directory record Official record
Conditions
Fractures
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
Ohio Orthopedic Center of Excellence
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Upper Arlington, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 3, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Results available

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

NCT00393380
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic, Anemia, Aplastic, Myelofibrosis, Lymphoma, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute
Interventions
Parathyroid Hormone (teriparatide)
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Gainesville, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Sep 3, 2026, 6:54 PM EDT
Completed No phase listed Observational Results available

Study of FORTEO Use in Subjects in the Community Setting

NCT01078805
View directory record Official record
Conditions
Osteoporosis
Interventions
FORTEO
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
4,167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide

NCT02195895
View directory record Official record
Conditions
Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions
Alendronate, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)

NCT00826228
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Spinal Cord Injury
Interventions
teriparatide, weight-bearing
Drug · Other
Lead sponsor
Thomas J. Schnitzer
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

NCT00051558
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCT00079924
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
teriparatide, aldrenodate, raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Sep 3, 2026, 6:54 PM EDT
Terminated Not applicable Interventional Results available

Stem Cell Recruitment in Osteoporosis Therapy

NCT01656629
View directory record Official record
Conditions
Low Bone Density
Interventions
Teriparatide, Alendronate, calcium and vitamin D
Drug · Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis

NCT00004993
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid hormone (hPTH 1-34)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 3, 2026, 6:54 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

NCT02130973
View directory record Official record
Conditions
Osteoporosis
Interventions
Standard Clinical Practice Regimen, Experimental Cyclic Regimen
Drug
Lead sponsor
Health Research, Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Study of PF708 and Forteo in Healthy Subjects

NCT02656810
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide
Drug
Lead sponsor
Pfenex, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

NCT00926380
View directory record Official record
Conditions
Osteoporosis
Interventions
denosumab, teriparatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 3, 2026, 6:54 PM EDT
Withdrawn No phase listed Observational

Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis

NCT03217513
View directory record Official record
Conditions
Osteoporosis, Knee Osteoarthritis
Interventions
Not listed
Lead sponsor
Edward Fox
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 3, 2026, 6:54 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women

NCT00697463
View directory record Official record
Conditions
Menopause, Fracture, Osteoporosis
Interventions
Teriparatide (PTH 1-34)
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 48 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 3, 2026, 6:54 PM EDT